Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection

Przeglad Gastroenterologiczny

Volumn 13, Issue 3, 2018, Pages 213-217

  Konrad, Paulina ^a   Chojnacki, Jan ^a   Gasiorowska, Anita ^a   Rudnicki, Cezary ^a   Kaczka, Aleksandra ^a   Chojnacki, Cezary ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Amoxicillin; Helicobacter pylori; Rifaximin; Small intestinal bacterial overgrowth; Therapy

Indexed keywords

EID: 85053778017     PISSN: 18955770     EISSN: 18974317     Source Type: Journal    
DOI: 10.5114/pg.2018.74228     Document Type: Article

References (34)

1. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010; 8: 504-8.
2. Marlicz W, Loniewski I, Grimes DS, Quigley EM. Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine. Mayo Clin Proc 2014; 89: 1699-709.
3. Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol 2015; 21: 6817-9.
4. Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011; 41: 380-6.
5. Osawa H, Kita H, Ohnishi H, et al. Changes in plasma ghrelin levels, gastric ghrelin production, and body weight after Helicobacter pylori cure. J Gastroenterol 2006; 41: 954-61.
6. Jang EJ, Park SW, Park JS, et al. The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. J Gastroenterol Hepatol 2008; 23 Suppl 2: 278-85.
7. Ulasoglu C, Isbilen B, Doganay L, et al. Effect of Helicobacter pylori eradication on serum ghrelin and obestatin levels. World J Gastroenterol 2013; 19: 2388-94.
8. Gen R, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J 2010; 103: 190-6.
9. Albaker WL. Helicobacter pylori infection and its relationship to metabolic syndrome: is it a myth or fact? Saudi J Gastroenterol 2011; 17: 165-9.
10. Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients 2014; 6: 5583-99.
11. Schwiertz A, Taras D, Schäfer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 2010; 18: 190-5.
12. Stachowicz N, Kiersztan A. The role of gut microbiota in the pathogenesis of obesity and diabetes. Postepy Hig Med Dosw 2013; 67: 288-303.
13. Sugano K, Tack J, Kuipers EJ, et al. Faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353-67.
14. Bayeli PF, Mariottini M, Lisi L, et al. Guidelines on intestinal dysmicrobism (SIBO Small Intestine Bacterial Overgrowth). Minerva Gastroenterol Dietol 1999; 45: 297-308.
15. Gasbarrini A, Lauritano EC, Gabrielli M, et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 2007; 25: 237-40.
16. Enko D, Kriegshäuser G. Functional 13C-urea and glucose hydrogen/methane breath tests reveal significant association of small intestinal bacterial overgrowth in individuals with active Helicobacter pylori infection. Clin Biochem 2017; 50: 46-9.
17. Schulz C, Koch N, Schütte K, et al. H. pylori and its modulation of gastrointestinal microbiota. J Dig Dis 2015; 16: 109-17.
18. Llorca L, Pérez-Pérez G, Urruzuno P, et al. Characterization of the gastric microbiota in a pediatric population according to Helicobacter pylori status. Pediatr Infect Dis J 2017; 36: 173-8.
19. Sheh A, Fox JG. The role of the gastrointestinal microbiome in Helicobacter pylori pathogenesis. Gut Microbes 2013; 4: 505-31.
20. Lauritano EC, Gabrielli M, Scarpellini E, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009; 13: 111-6.
21. Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2017; 45: 604-16.
22. Mégraud F, Bouffant F, Camou Juncas C. In vitro activity of rifaximin against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1994; 13: 184-6.
23. Sunny J Jr, Garcia CJ, McCallum RW. Interpreting the lactulose breath test for the diagnosis of small intestinal bacterial overgrowth. Am J Med Sci 2016; 351: 229-32.
24. Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2013; 38: 925-34.
25. Di Stefano M, Miceli E, Missanelli A, et al. Absorbable vs. non-absorbable antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind-loop syndrome. Aliment Pharmacol Ther 2005; 21: 985-92.
26. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs 2009; 18: 349-58.
27. Holton J, Vaira D, Menegatti M, Barbara L. The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J Antimicrob Chemother 1995; 35: 545-9.
28. De Giorgio R, Stanghellini V, Barbara G, et al. Rifaximin and Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci 1997; 1: 105-10.
29. Quesada M, Sanfeliu I, Junquera F, et al. [Evaluation of Helicobacter pylori susceptibility to rifaximin]. Gastroenterol Hepatol 2004; 27: 393-6.
30. Gasbarrini A, Gasbarrini G, Pelosini I, Scarpignato C. Eradication of Helicobacter pylori: are rifaximin-based regimens effective? Digestion 2006; 73 Suppl 1: 129-35.
31. Nizhevich AA, Shcherbakov PL, Akhmadeeva ÉN, Khasanov RS. Rifaximin in combined treatment of the Helicobacter pylori infection in childhood. Eksp Klin Gastroenterol 2011; 1: 85-7.
32. Yun SP, Seon HG, Ok CS, et al. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver 2012; 6: 452-6.
33. Choi KH, Chung WC, Lee KM, et al. Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci 2011; 26: 785-90.
34. Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol 2014; 20: 1517-28.